Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson's disease.

Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
Brain (Impact Factor: 10.23). 02/2011; 134(Pt 2):359-74. DOI: 10.1093/brain/awq332
Source: PubMed

ABSTRACT Both phenotype and treatment response vary in patients with Parkinson's disease. Anatomical and functional imaging studies suggest that individual symptoms may represent malfunction of different segregated networks running in parallel through the basal ganglia. In this study, we use a newly described, electrophysiological method to describe cortico-subthalamic networks in humans. We performed combined magnetoencephalographic and subthalamic local field potential recordings in thirteen patients with Parkinson's disease at rest. Two spatially and spectrally separated networks were identified. A temporoparietal-brainstem network was coherent with the subthalamic nucleus in the alpha (7-13 Hz) band, whilst a predominantly frontal network was coherent in the beta (15-35 Hz) band. Dopaminergic medication modulated the resting beta network, by increasing beta coherence between the subthalamic region and prefrontal cortex. Subthalamic activity was predominantly led by activity in the cortex in both frequency bands. The cortical topography and frequencies involved in the alpha and beta networks suggest that these networks may be involved in attentional and executive, particularly motor planning, processes, respectively.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review surveys recent trends in the use of local field potentials—and their non-invasive counterparts—to address the principles of functional brain architectures. In particular, we treat oscillations as the (observable) signature of context-sensitive changes in synaptic efficacy that underlie coordinated dynamics and message-passing in the brain. This rich source of information is now being exploited by various procedures—like dynamic causal modelling—to test hypotheses about neuronal circuits in health and disease. Furthermore, the roles played by neuromodulatory mechanisms can be addressed directly through their effects on oscillatory phenomena. These neuromodulatory or gain control processes are central to many theories of normal brain function (e.g. attention) and the pathophysiology of several neuropsychiatric conditions (e.g. Parkinson's disease).
    Current Opinion in Neurobiology. 01/2015; 31:1–6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The last decade has seen major progress at all levels of neuroscience, from genes and molecules up to integrated systems-level models of brain function. In particular, there have been advances in the understanding of cell-type-specific contributions to function, together with a clearer account of how these contributions are coordinated from moment to moment to organise behavior. A major current endeavor is to leverage this knowledge to develop new therapeutic approaches. In Parkinson’s disease, there are a number of promising emerging treatments. Here, we will highlight three ambitious novel therapeutic approaches for this condition, each robustly driven by primary neuroscience. Pharmacogenetics genetically re-engineers neurons to produce neurotrophins that are neuroprotective to vulnerable dopaminergic cells or to directly replace dopamine through enzyme transduction. Deep brain stimulation (DBS) is undergoing a transformation, with adaptive DBS controlled by neural signals resulting in better motor outcomes and significant reductions in overall stimulation that could reduce side effects. Finally, optogenetics presents the opportunity to achieve cell-type-specific control with a high temporal specification on a large enough scale to effectively repair network-level dysfunction.
    Current Biology 09/2014; 24(18):R898–R909. · 9.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's Disease (PD), characterized by tremor, rigidity, and bradykinesia, is one of the most prevalent neurodegenerative disorders in the world. The pathological hallmark of PD is the loss of dopaminergic cells in the substantia nigra and other brain regions. The pathophysiological mechanisms by which dopaminergic cell loss leads to the motor manifestations of PD are yet to be fully elucidated. A growing body of evidence has revealed abnormal neuronal oscillations within and between multiple brain regions in PD. Unique oscillatory patterns are associated with specific motor abnormalities in PD. Therapies, such as dopaminergic medication and deep brain stimulation that disrupt these abnormal neuronal oscillatory patterns produce symptomatic improvement in PD patients. These findings emphasize the importance of abnormal neuronal oscillations in the pathophysiology of PD, making the disruption of these oscillatory patterns a promising target in the development of effective PD treatments.
    Frontiers in bioscience (Landmark edition). 01/2014; 19:1291-1299.